Novo Nordisk A/S New data will highlight the breadth of semaglutide evidence across the cardiometabolic spectrum, including obesity, type 2 diabetes, cardiovascular, kidney and fatty liver disease, and new data on Wegovy® pill, Wegovy® 7.2 mg and Ozempic® 2.0 mg Real-world evidence from the OCTANE study will provide insights into Wegovy® pill use in adults with overweight or obesity, including weight outcomes, treatment switching and patient-reported outcomes CagriSema and amylin-based pipeline data will provide new insights into appetite regulation, eating behaviour, food noise, body composition and bone health (bone remodelling mechanisms).
Nous affichons publiquement l'idee principale. Creez un compte gratuit pour lire l'article complet, l'enregistrer, le commenter et le relier au contexte marches et OSINT.